Mimi Tran1, Evan Wood2,3, Thomas Kerr2,3, Sophie Patterson2,4, David Bangsberg5,6, Huiru Dong2, Silvia Guillemi2,3, Julio Sg Montaner2,3, M-J Milloy2,3. 1. Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 2. British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada. 3. Division of AIDS, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 4. Faculty of Health Studies, Simon Fraser University, Vancouver, BC, Canada. 5. Massachusetts General Hospital Centre for Global Health, Boston, MA, USA. 6. Harvard Medical School, Harvard University, Boston, MA, USA.
Abstract
BACKGROUND: Although treatment-as-prevention (TasP) efforts are a new cornerstone of efforts to respond to the HIV/AIDS pandemic, their effects among people who use drugs (PWUD) have not been fully evaluated. This study characterizes temporal trends in CD4+ T-cell (CD4) count at ART initiation and rates of virological response among HIV-positive PWUD during a TasP initiative. METHODS: We used data on individuals initiating ART within a prospective cohort of PWUD linked to comprehensive clinical records. Using multivariable linear regression, we evaluated the relationship between CD4 count prior to ART initiation and year of initiation and time to HIV-1 RNA viral load <50 copies/ml following initiation using Cox proportional hazards modelling. RESULTS: Among 355 individuals, CD4 count at initiation rose from 130 to 330 cells/ml from 2005 to 2013. In multivariable regression, initiation year was significantly associated with higher CD4 count (β=29.5 cells per year, 95% CI 21.0, 37.9). Initiating ART at higher CD4 counts was significantly associated with optimal viral response (adjusted hazard ratio =1.13 per 100 cells/ml increase, 95% CI 1.05, 1.22). CONCLUSIONS: Increases in CD4 cell count at initiation over time was associated with superior virological response, consistent with the aims of the TasP initiative.
BACKGROUND: Although treatment-as-prevention (TasP) efforts are a new cornerstone of efforts to respond to the HIV/AIDS pandemic, their effects among people who use drugs (PWUD) have not been fully evaluated. This study characterizes temporal trends in CD4+ T-cell (CD4) count at ART initiation and rates of virological response among HIV-positive PWUD during a TasP initiative. METHODS: We used data on individuals initiating ART within a prospective cohort of PWUD linked to comprehensive clinical records. Using multivariable linear regression, we evaluated the relationship between CD4 count prior to ART initiation and year of initiation and time to HIV-1 RNA viral load <50 copies/ml following initiation using Cox proportional hazards modelling. RESULTS: Among 355 individuals, CD4 count at initiation rose from 130 to 330 cells/ml from 2005 to 2013. In multivariable regression, initiation year was significantly associated with higher CD4 count (β=29.5 cells per year, 95% CI 21.0, 37.9). Initiating ART at higher CD4 counts was significantly associated with optimal viral response (adjusted hazard ratio =1.13 per 100 cells/ml increase, 95% CI 1.05, 1.22). CONCLUSIONS: Increases in CD4 cell count at initiation over time was associated with superior virological response, consistent with the aims of the TasP initiative.
Authors: A M Cescon; C Cooper; K Chan; A K Palmer; M B Klein; N Machouf; M R Loutfy; J Raboud; A Rachlis; E Ding; V D Lima; J S G Montaner; S B Rourke; M Smieja; C Tsoukas; R S Hogg Journal: HIV Med Date: 2010-11-08 Impact factor: 3.180
Authors: M J Milloy; Thomas Kerr; Jane Buxton; Tim Rhodes; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood Journal: J Infect Dis Date: 2011-05-01 Impact factor: 5.226
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall Journal: Lancet Date: 2010-07-16 Impact factor: 79.321
Authors: Andrew Anglemyer; George W Rutherford; Philippa J Easterbrook; Tara Horvath; Marco Vitória; Michael Jan; Meg C Doherty Journal: AIDS Date: 2014-03 Impact factor: 4.177